Topic: vaccine manufacturing
A former deputy director of the old China FDA has been handed to the prosecutors over suspected duty-related crimes.
Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.
WuXi Biologics is forming a human vaccine-focused CDMO joint venture with local veterinary vaccine firm Shanghai Hile Bio-Technology.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.
Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.
Ex-Roche scientists were charged with stealing trade secrets; Astellas invested in gene and cell therapy; Takeda touted growth in key focus areas.
If the German contract manufacturer delivers all projects over the 10-year course, it could receive up to $80 million.
A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.
No production or safety problems were found at the other 45 vaccine manufacturers in China, the country's drug regulator says.